$0.00
Shopping Cart
Facebook-f Instagram
DONATE
Donate

Clinical Trial Record

Return to Clinical Trials

Investigator's Initiated Phase II Study for Pancreatic Cancer Patients

2013-12

2014-10

N/A

10

Study Overview

Investigator's Initiated Phase II Study for Pancreatic Cancer Patients

The purpose of this study is to evaluate the efficacy, safety and tolerability of TL-118 alone or in combination with pancreatic cancer chemotherapy.

N/A

  • Pancreatic Cancer
  • DRUG: TL-118
  • TLH-207

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2012-07-23  

N/A  

2013-12-04  

2012-08-06  

N/A  

2013-12-05  

2012-08-07  

N/A  

2013-12  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Na

Interventional Model:
Single Group

Masking:
None

Arms and Interventions

Participant Group/ArmIntervention/Treatment
EXPERIMENTAL: TL-118 alone or with pancreas cancer chemotherapy

DRUG: TL-118

  • TL-118 investigational product is supplied as an oral liquid for daily administration at a specific dosing regimen. Treatment protocol includes weekly therapy cycles
Primary Outcome MeasuresMeasure DescriptionTime Frame
Clinical Benefit MeasurementClinical Benefit Measurement is a composite of measurements of pain (analgesic consumption and pain intensity), performance status and weight. Clinical benefit requires an improvement in at least one parameter, without worsening in any others, sustained for at least 4 weeksBaseline up to 2 years
Secondary Outcome MeasuresMeasure DescriptionTime Frame
Safety and tolerabilitySafety and tolerability profiles will be judged by: * Local and systemic toxicities. * Number, type and degree of toxicities as measured by the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) v4.0Baseline up to 2 years
Response Rate (RR)RR measured every 8 weeks after enrollment up to 2 years
Overall SurvivalOS measured at 16 and 52 weeks after treatment initiation or at death, whichever comes first up to 2 years
Progression Free Survival (PFS)PFS measured at 8 weeks after enrollment until the date of first documented progression or date of death, whichever comes first, up to 2 years

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Ayala Huberrt, MD

Phone Number:

Email: AyalaH@hadassah.org.il

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    Inclusion Criteria:
    1. Age at least 18 years at enrollment. 2. Locally Advanced Pancreatic Cancer and/or Metastatic Pancreatic Cancer which failed to respond to one or two lines of chemotherapy 3. The patient has histologically or cytologically confirmed pancreatic cancer. 4. Patient has measurable disease by radiological imaging techniques as defined according to Response Evaluation Criteria in Solid Tumors (RECIST). 5. ECOG performance status ≤ 2 6. Adequate renal function. 7. Adequate hepatic function 8. Adequate bone marrow reserve - 9. Resolution of prior therapy acute adverse events. 10. Patient is capable of swallowing. 11. Patient's Informed Consent.
    Exclusion Criteria:
    1. Hypersensitivity to one or more of the TL-118 active components 2. Known Glucose-6-phosphate-dehydrogenase deficiency (G6PD). 3. Known CNS or Brain metastases 4. Patient has received 3 or more different prior chemotherapies for the treatment of pancreatic cancer 5. Any significant change in treatment within the 14 days before screening or an un-stable medical condition that may affect patient participation or evaluation in the study. 6. Concurrent use of any other investigational product or within 28 days before study entry. 7. Chronic treatment with: (a) immunosuppressive agent other than systemic corticosteroid, (b) patients who are under chronic treatment with NSAIDs with the exception of Aspirin at a daily dose ≤ 100mg. 8. Use of supplements or complementary medicines/botanicals, except for conventional multivitamin supplements, calcium, selenium and soy supplements. 9. Patients at increased risk of gastro intestinal bleeding such as patients with known active gastro intestinal ulcer, erosive gastritis or varices, as confirmed by gastroscopy performed within one year before screening. 10. Serious or uncontrolled co-existent diseases that are likely to significantly increase the risks associated with TL-118 therapy (e.g. severe cardiovascular disease, congestive heart failure, recent myocardial infarction, significant vascular disease, active or uncontrolled autoimmune disease, active or uncontrolled infection). 11. Patient has known historical or active infection with HIV, hepatitis B, or hepatitis C 12. Serious or non-healing wound, ulcer or bone fracture. 13. Circumstances likely to interfere with absorption of orally administrated drugs. 14. History of noncompliance to medical regimens or coexisting conditions precluding full compliance with study protocol, or any other condition that in the discretion of the Investigator may preclude safe and complete study participation. 15. Subjects unwilling or unable to comply with study protocol. 16. Know pregnancy or breast-feeding women. 17. Women of child bearing potential not exercising two methods of contraception.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

NPCF Pop up

Make-A-Will Month

Snag 6508be92
Learn More
Donate Now Online
Other Ways to Donate